Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Sotalol
SORBITOL · Sotalol (base and/or unspecified salts) · SOTALOL · Sotolol · dl-sotalol · Betacotdone · beta-Cardone · AURORA KA-855
식별자 및 물리적 특성
| CAS No. | 3930-20-9 |
|---|---|
| 분자식 | C12H20N2O3S |
| 평균 분자량 | 272.37 g/mol |
| 단동위원소 질량 | 272.1194635 g/mol |
| SMILES | CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1 |
| InChIKey | ZBMZVLHSJCTVON-UHFFFAOYSA-N |
| PubChem CID | 5253 |
| ChEMBL | CHEMBL471 |
| ChEBI | CHEBI:63622 |
| EC No. | 977-025-7 |
| DTXSID | DTXSID0023589 |
화학 및 물리적 성질
| XLogP | 0.2 |
|---|---|
| 극성 표면적 | 86.8 |
| 수소 결합 공여자 수 | 3 |
| 수소 결합 수용자 수 | 5 |
| 회전 가능 결합 수 | 6 |
| 무거운 원자 수 | 18 |
| 형식 전하 | 0 |
| 복잡도 | 330 |
| 의약품 | PharmaceuticalsPharmaceuticals -> Used in Switzerland |
| LogP(분배 계수) | 1.10.53 |
| 용해도 | 7.82e-01 g/L클로로포름(약간 용해됨, 가열), 메탄올(약간 용해됨, 초음파 처리) |
| Human Drugs | Breast FeedingLactationMilk, HumanAntihypertensive AgentsAdrenergic Beta-AntagonistsAntiarrhythmicsPharmaceuticals |
| 녹는점 | 206.5 - 207 °C206.5-207 °C |
| Physical Description | Solid |
| Dissociation Constants | 9.76 |
| Collision Cross Section | 167 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 끓는 점 | 443.3±55.0 °C(Predicted) |
| 밀도 | 1.298 g/cm3 |
| 저장 조건 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | pK1 8.2, pK2 9.8(at 25℃) |
| 색상 | 연한 노란색에서 밝은 노란색까지 |
| BCS Class | 1 |
| 안정성 | 흡습성 |
| InChI | InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 |
| InChIKey | ZBMZVLHSJCTVON-UHFFFAOYSA-N |
| SMILES | CS(NC1=CC=C(C(O)CNC(C)C)C=C1)(=O)=O |
| NIST | Methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-(3930-20-9) |
| EPA | Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (3930-20-9) |
안전 및 규제
| GHS 분류 | DangerH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P203, P260, P263, P264, P264+P265, P270, P280, P302+P352, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%) |
| Hepatotoxicity | Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on sotalol and are usually transient and asymptomatic, resolving even with continuation of therapy. Sotalol has been linked to a single case of clinically apparent liver injury, with onset of an acute hepatitis-like syndrome with prolonged jaundice 12 weeks after sotalol was initiated. The injury improved but did not resolve with discontinuation of sotalol. In large case series of drug induced liver disease and acute liver failure, sotalol has not been listed as a cause. Other beta-blockers have been linked to rare instances of acute clinically apparent liver injury with a latency to onset ranging from 4 to 24 weeks, a hepatocellular pattern of serum enzyme elevations and a mild, self-limiting course without evidence of hypersensitivity or autoimmune reactions. |
| 유해 작용 | Sotalol's adverse effect profile is inherent in the mechanisms of action as both a potassium channel blocker and a non-cardioselective β-blocker. The potassium channel blockade, primarily in phase 3 of the cardiac action potential, prolongs the QTc. Thus, the electrocardiogram (ECG) must be monitored upon initiating sotalol or adding other QTc-prolonging medications. Prolongation of the QT interval occurs in 1% to 2% of cases, which could lead to torsades de pointes or new ventricular tachycardia/ventricular fibrillation. |
| 독성 요약 | Sotalol toxicity is inherent due to the mechanism of action as both a potassium channel blocker and a non-cardioselective β-blocker and mirrors the adverse effect profile. The most obvious and potentially problematic sign of toxicity is concentration-related QTc prolongation. If QTc is over 500 ms during initiation, the sotalol dose should be reduced or discontinued. If QTc exceeds 520 ms during the maintenance phase of dosing, the clinician should either reduce the dose or discontinue sotalol. |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)sotalolDILI NegativeOralDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 위험 문구(R) | 36/37/38 |
| 위험 표시 | Xi |
| 안전 문구(S) | 26-36 |
용도
일반 설명
Sotalol, 4＇[1-hydroxy-2-(isopropylamino)ethyl]methylsulfonanilide (Betapace), is a relatively new antiarrhythmicdrug, characterized most often as a class IIIagent, and although it has effects that are related to the classII agents, it is not therapeutically considered a class II antiarrhythmic.It contains a chiral center and is marketed as theracemic mixture. Because of its enantiomers, its mechanismof action spans two of the antiarrhythmic drug classes. Thel(-) enantiomer has both β-blocking (class II) and potassiumchannel-blocking (class III) activities. The d(+) enantiomerhas class III properties similar to those of the (-) isomer,but its affinity for the -adrenergic receptor is 30 to 60 timeslower.